The pan-LOX inhibitor NDGA and the selective 12-LOX inhibitor baicalein, both exhibiting also antioxidant properties, were shown to reduce the expression of the vascular endothelial growth factor (VEGF) in human prostate cancer PC3 cells through inhibition of Sp1 (specificity protein 1) which is the transcription factor responsible for 12-LOX-mediated stimulation of VEGF (Nie et al., 2006). The gene discussed is ALOX15; the disease is prostate cancer.